Login to Your Account



FDA Dings the Takeda/Furiex Type II Diabetes Combo

By Catherine Shaffer
Staff Writer

Wednesday, May 2, 2012
The FDA issued a complete response letter to Takeda Pharmaceutical Co. Ltd. last week regarding new drug applications for alogliptin and fixed-dose combinations of alogliptin and pioglitazone for Type II diabetes, products partnered with Furiex Pharmaceuticals Inc.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription